Results · Apr-Jun 2026 · filed 10 Aug 2026
Gland Pharma Q1 FY27 results
Very strongVery strong: sales up 15% or more & profit up 25% or more on the same quarter last year, with a wider operating margin.
Sales grew 20% to ₹1,800 crore from ₹1,506 crore in Apr-Jun 2025.
Operating profit grew 33% to ₹489 crore, an operating margin of 27.2% (up 2.8 points from a year ago).
Net profit grew 47% to ₹317 crore from ₹215 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +3%, net profit −14%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 1,800 | 1,506 | +20% |
| Operating profit (EBITDA) | 489.4 | 367.8 | +33% |
| Operating margin | 27.2% | 24.4% | +2.8 pts |
| Net profit | 317.0 | 215.5 | +47% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Apr–Jun 2026 revenue grew 20% from a year earlier to ₹1,800 crore with PAT up 47% to ₹317 crore & adjusted EBITDA margin at 28%. Management announced a major CDMO contract with USD90-100 million peak revenue potential from 2029 & expects 15-20% growth ahead with capacity expansion underway.
The last 7 quarters
Filings that week
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Change in Management
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 10 Aug 2026Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2026
- 10 Aug 2026Unaudited Financial Results For The Quarter Ended June 30, 2026
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.